Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Infection control wikipedia , lookup
Eradication of infectious diseases wikipedia , lookup
HIV and pregnancy wikipedia , lookup
Diseases of poverty wikipedia , lookup
Harm reduction wikipedia , lookup
Epidemiology of HIV/AIDS wikipedia , lookup
Placebo-controlled study wikipedia , lookup
TB: A Global Emergency • 1/3 of the world (2 billion people) infected • 1 person infected/second resulting in >30 million new infections, 8 million new cases • Left untreated 1/3 die, 1/3 self-cure, 1/3 remain infectious • TB kills 1 person every 10 seconds = 5000/day = 2-3 million each year 22 High Burden Countries • • • • • • • • • • • India China Indonesia Bangladesh Pakistan Nigeria Philippines South Africa Ethiopia Vietnam Russian Federation • • • • • • • • • • • Congo Brazil Tanzania Kenya Thailand Myanmar Afghanistan Uganda Peru Zimbabwe Cambodia TB: Clinical Features • TB is caused by Mycobacterium tuberculosis • TB can affect any organ system: bone, kidney, CNS; 80% are pulmonary • Classic pulmonary systems of active disease: cough > 3 weeks duration, chest pain, bloody sputum • Classic systemic symptoms: fever, night sweats, weight loss, malaise • Treated for many years with long hospitalization, surgery, myriad of drugs leading to belief that TB is not treatable or treatment worse than disease. TB Infection vs TB Disease • TB infection – organism is present, but dormant, cannot infect others • TB disease – person is sick and can transmit disease to others if in lungs • 10% of individuals with TB infection will develop TB disease • Each individual with active TB can infect 10-15 people/year When does TB infection become disease? • Most likely to occur in first two years after infection • If person becomes immunocompromised – HIV – Cancer – Chemotherapy – Poorly controlled diabetes – malnutrition The 5 Essential Components of the DOTS Strategy • Government commitment to a National TB Program • Priority to detect infectious cases by sputum smear microscopy • Standardized regimens of short-course chemotherapy, given under direct observation for , at least, the intensive phase • Regular, uninterrupted supply of anti-TB meds • Monitoring system for program supervision and evaluation 1. Political/Administrative Commitment • Perception of TB as a priority problem with real solution • Government acknowledges importance of disease • Public commitment to National TB Program (NTP) • Support for personnel, training, transportation, drugs 2. Accurate Diagnosis=Sputum Microscopy • Identification/cure of infectious cases (smear+) is highest priority of TB control – Smear+s 4-20 times more infectious; may infect 10-15/year; more likely to die if untreated • Timely results to reduce potential for transmission • Quality assurance/training--national reference lab is key Diagnosis of pulmonary TB Cough 3 weeks If 1 positive, X-ray and evaluation AFB X 3 If 2/3 positive: Anti-TB Rx If negative: Broad-spectrum antibiotic 10-14 days If symptoms persist, repeat AFB smears, X-ray If consistent with TB Anti-TB Treatment Chest X-ray (CXR) as Diagnostic Tool • No CXR pattern is typical – Many TB cases are missed (10-15% culture+s) – Many non-TB cases misdiagnosed (40% diagnosed by CXR alone do not have active TB • Previous MD training emphasized CXR as best diagnostic tool • Often reaction to poor, inaccurate, or unavailable lab services X-ray-based evaluation causes over-diagnosis of TB 100 Overdiagnosis 80 60 40 20 0 Diagnosed by Xray alone NTI, Ind J Tuberc, 1974 Actual cases Microscopy is a more specific test than X-ray for TB diagnosis 100 98% Specificity 80 60 50% 40 20 0 AFB Microscopy X-ray 3. Adequate Supply of Drugs • Treatment requires regular doses of combination regimens for >6 months • Identification of an adequate supply of appropriate drugs for patients prior to initiation of treatment essential • If regimens incomplete, real chance of development of drug-resistant strains which are hard or impossible to cure • Requires continuum of drug management services: selection, procurement, distribution, use. 4. Directly Observed Treatment • Why? Many patients don’t take medicines regularly, even if excellent health education provided • Who? All patients... impossible to predict which patient will take medicine (1/3 not adherent) • What? Observer watches and helps patient swallow tablets • Where? Anywhere! (home, clinic, work, school, etc) • Who does it? HCW, community liaisons, teachers, Direct observation ensures treatment for entire course with the right drugs, in the right doses, at the right intervals DOT is necessary even when drug supply ensured 100% 88% Treatment Success 80% 61% 60% 40% 20% 0% DOT Chaulk CP. JAMA 1998;279:943-8 No DOT DOT prolongs survival of HIV-infected TB patients Survived 56.7% Survived 85.4% Died 43.3% SCC without DOT SCC with DOT Died 14.6% 5. Systematic Monitoring/Accountability • • TB Register Recording system is simple to use, essential, integrated component of DOTS enabling – Monitoring of patient outcomes – Evaluation of program performance – Analysis of epidemiologic data – Identification of areas for OR Every level of health system accountable for patient diagnosis and cure; “report card” TB and HIV/AIDS • • • • HIV negatively impacts TB and TB negatively impacts HIV HIV+ individuals infected with TB are 30x more likely to develop TB disease TB is leading cause of death among HIV+, accounting for ~40% of AIDS deaths HIV increases the prevalence of active TB in HIV- and HIV+ populations Multidrug-Resistant TB (MDRTB) • • • • • Defined as resistance to INH and RIF Caused by inconsistent or partial treatment of susceptible TB (primary) Cure rates <70% cause the epidemic and drug resistance to increase Drugs are more toxic and expensive, and less effective; treatment more difficult/expensive, and more likely fatal in developing world Poorly supervised, incomplete treatment is worse than no treatment at all: Prevention of MDRTB is the primary strategy to address MDRTB USAID TB Strategy • Support for the STOP TB Initiative • Establishment of field sites/programs to serve as models for innovative wide-scale TB control • Investigation/implementation of potential technologies and methodologies for TB prophylaxis, diagnosis, and treatment • Support for surveillance to monitor TB trends and identify MDRTB strains before they become widespread USAID Expanded Response • Continued investments in global and regional partnerships: – support for the Stop TB initiative – continued work with other USG agencies – Global partnership to develop new anti-TB drugs – Global Drug Facility – New International coalition of organizations and agencies including KNCV, IUATLD, WHO, CDC, ALA/ATS to provide TA/develop TB expertise – Continued support for coordinated research to optimize diagnostics and treatment regimens USAID Expanded Response • Expanded research investments – rapid and sensitive TB diagnostic tests – increase funding, work with our partners to mobilize efforts and expertise of PH workers, industry, academic researchers, donors, other partners in lab/OR components – Target collaborative efforts to develop costeffective TB drugs and combination therapies – Potential expansion to vaccine development USAID Expanded Response • Focused, expanded programs in key countries, targeting – countries of greatest need, defined by TB burden – countries with high HIV/AIDS prevalence – countries at risk of escalating MDR epidemics TB Country Programs USAID - 2001 New/Expanded Country Programs DR Congo Ethiopia Kenya Malawi Senegal Uganda Cambodia India* Indonesia Philippines* Russia* Brazil Dominican Republic Haiti Mexico On-Going Programs South Africa, Bolivia, El Salvador, Honduras, Peru, Central Asian Republics, Ukraine, Romania, SE Europe Regional *Existing program Partners/Implementers • Current – WHO, CDC, Fogarty/NIH, IUATLD, Gorgas Institute, MSH/RPM, PATH, QAP, FHI – TBCTA (TB Coalition for Technical Assistance) • Potential – NGOs (MSF, DOW, MERLIN) – Foundations, World Bank, US Model Centers Global Programs/Mechanisms • Global/Bureau umbrella agreements with WHO and CDC • Multiple agreements to address technical areas: RPM, PATH, TBCTA • New interagency alliances under development for drug procurement/ management/development • Standard indicators already developed Common Health Assumptions not applicable to TB • Access is necessary but NOT sufficient – Drugs – Services • Not every health center/NGO site appropriate as TB care center • Poor program is worse than no program at all Priorities of TB Control • Make sure the person completes TB treatment! • Do not cause drug resistance; a poor TB program is worse than no TB program! • Treating non-pulmonary cases and those infected without active disease are of lesser public health importance With TB, treatment is more than treatment, treatment is prevention Role of Rifampicin • Necessary for short-course treatment • Essential for at least first 2 months of regimens • Bactericidal for rapidly dividing and slow-growing organisms • Prevents emergence of resistance to other drugs • Intermittent treatment more effective than daily treatment in animal model; equally effective in clinical trials Role of Isoniazid • • • • Mainstay of anti-TB treatment Life saving in TB meningitis Bactericidal for rapidly dividing organisms Prevents emergence of resistance to other drugs • Intermittent treatment more effective than daily treatment in animal model; equally effective in clinical trials • Safe and effective for preventive treatment DOTS can reduce the TB burden Annual percentage decline in incidence/prevalence 0 -5 -10 -15 -20 -25 Edinburgh Beijing New York Peru Cuba S. Korea Uruguay Chile TB: the leading single infectious cause of death in SE Asia 800 Number of deaths (1000s) Deaths from infectious agents in South-East Asia 700 600 500 400 300 200 100 0 Tuberculosis HIV Measles STD Malaria Tropical Diseases 33 TB is a Leading Killer of Women Deaths among women 605,000 538,000 493,000 101,000 48,000 Tropical Diseases STD Maternal Mortality Malaria TB Diagnosis of pulmonary TB Patients with TB feel ill and seek care promptly Active case finding is unnecessary and unproductive Microscopy is appropriate technology, indicating infectiousness, risk of death, and priority for treatment X-ray is non-specific for TB diagnosis Serological and amplification technologies (PCR, etc.) currently of no proven value in TB control Proportion of pulmonary TB patients with positive AFB smears 70 60 HIV Negative AFB positivity in TB patients Early HIV 50 40 30 20 10 0 Late HIV Prompt treatment of infectious cases reduces spread of TB • Smear-positive patients usually seek care • Smear-positive patients are 4-20 times more infectious • Untreated, a smear-positive patient may infect 10-15 persons/year • Smear-positive patients are much more likely to die if untreated Rouillon A. Tubercle 1976;57:275-99 Severe and less severe forms of extra-pulmonary TB Severe Less Severe Meningitis Lymph nodes Miliary Pleural effusion (unilateral) Pericarditis Bone (excluding spine) Bilateral or extensive pleural effusion Peripheral joint Spinal Intestinal TB/HIV, A Clinical Manual, World Health Organization 1996 Role of Pyrazinamide • Essential for 6- and 8-month regimens • No benefit if given > 2 months • Relatively ineffective at preventing emergence of resistance to other drugs Pyrazinamide essential for first two months of 6/8-month treatment Relapses (%) 100 Relapses 80 60 40 20 3.4% 10.3% 0 Pyrazinamide Am Rev Respir Dis 1987;136:1339-42 No Pyrazinamide Role of Ethambutol/ Streptomycin • Prevent emergence of resistance to other drugs given • Hasten sputum conversion • Bacteriostatic or weakly bactericidal against rapidly dividing organisms Relapse rates low with directly observed treatment in both HIV(+) and HIV(-) patients Relapse (%) 100 80 60 Relapse rates 40 20 3% 5% HIV-uninfected HIV-infected 0 Am J Respir Crit Care Med 1996:154:1034-38 Adverse reactions to anti-TB drugs Drugs Isoniazid Adverse reactions Peripheral neuropathy Hepatitis Gastroentestinal (anorexia, nausea, Rifampicin Pyrazinamide Ethambutol vomiting, abdominal pain) Hepatitis Reduced effectiveness of oral contraceptive pill Joint pains Hepatitis Optic neuritis Auditory &vestibular nerve damage Streptomycin (also tofoetus) Renal damage Management of Drug Logistics CHOICE Quantification Financing USE Information for user & for consumer Management of Stocks DISTRIBUTION STORAGE Re-packaging Transportation Adequate buffer stocks must be maintained at national, state/regional, and local levels PURCHASE Tender bids Order Quality Control